Waters Introduces Mass Detector for Chromatography Separations - - BioPharm International

ADVERTISEMENT

Waters Introduces Mass Detector for Chromatography Separations


Waters QDaThe Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations. The detector, introduced on Oct. 7 by Waters Corp., is now shipping worldwide.

Designed as a component of a chromatographic system, the ACQUITY QDa Detector is compatible with Waters ACQUITY UltraPerformance LC, ACQUITY UltraPerformance Convergence Chromatography, Alliance high performance liquid chromatography and Waters supercritical fluid chromatography and LC-based purification systems.

The system is designed for analytical scientists who need mass spectral data without the complexity of a mass spectrometer. It features automated sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. The detector generates the high quality mass spectral data expected of a single quadrupole mass spectrometer in a mass detector no bigger than a photodiode array (PDA) detector.

The ACQUITY QDa Detector complements optical detection, such as the PDA detector, by confirming the identity of compounds with mass spectral information; quantifies compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection, the company reports.

The ACQUITY QDa Detector is available for separations systems running Empower 2 and 3 Chromatography Data System software, including enterprise deployment with automated qualification. The ACQUITY QDa Detector is also available now for MassLynx 4.1 Mass Spectrometry Software.

Source: Waters Corp.

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here